Temsirolimus, Metformin mTOR All MD Anderson Cancer Center Everolimus, trametinib, temozolomide and ABT- 888, or MK-1775 mTOR, MEK, PARP, Wee1 All National Cancer Institute Temsirolimus, neratinib mTOR, HER2 HER2+ Puma Biotechnology LGK974 Wnt pathway (Porcupine) TripleNegative Novartis JAK Ruxolitinib IL6/JAK/Stat pathway All Dana-Farber/Harvard Cancer Center Active, not recruiting Ruxolitinib JAK All Dana-Farber/Harvard Cancer Center Notch BMS-906024 Pan-Notch TripleNegative Bristol-Myers Squibb BMS-906024 Pan-Notch TripleNegative Chemotherapy Bristol-Myers Squibb PF-03084014 Notch All Docetaxel Pfizer RAF/MEK/ERK ALK Crizotinib/pazopanib/ pemetrexed ALK/VEG N/A MD Anderson Cancer Center X-396 ALK ALK+ Xcovery Pazopanib VEGFR Hormone+ Letrozole or anastro- zole GlaxoSmithkline Active, not recruiting Cabozantinib (XL184 ) VEGFR2, c-Met TripleNegative Dana-Farber/Harvard Cancer Center ErbB Erlotinib/metformin ERB1 (EGFR) TripleNegative Astellas Pharma/Komen Erlotinib ERB1 (EGFR) TripleNegative Chemotherapy and bevacizumab University of Washington Panitumumab ERB1 (EGFR) HER2- Nab-pacliatxel, car- boplatin, pluorouracil, epirubicin, cyclophos- phamide Celgene/MD Anderson Cancer Center Trastuzumab/lapatinib ErB1/ErB2 (HER2R) HER2+ GlaxoSmithKline Trastuzumab/lapatinib ErB2 (HER2R) HER2+ Combinations with capecitabine and cyclophosphamide University of Southern California Trastuzumab, pertu- zumab HER2 HER2+ Genentech, Susan G. Komen, GlaxoSmithKline Trastuzumab, lapatinib HER2 HER2+ GlaxoSmithKline, Genentech Lapatinib HER2 Hormone+_HER2- University of Kansas Completed as of 8/1 High-dose lapatinib ErB2 (HER2R) HER2+ University of California, San Francisco AdHER2/neu dendritic cell vaccine ERB2 HER2+ National Cancer Institute ONT-380, T-DM1 ERB2 HER2+ Oncothyreon ONT-380 ERB2 HER2+ Capecitabine and/or trastuzumab Oncothyreon Pertuzumab ErB2 HER2+ Protein-bound pacli- taxel/trastuzumab City of Hope Pertuzumab, trastuzum- ab, paclitaxel ErB2 HER2+ Memorial Sloan Kettering Pertuzumab/trastu- zumab ErB2 HER2+ Genentech Pertuzumab, trastuzum- ab, and eribulin ErB2 HER2+ Dana-Farber/Harvard Cancer Center PF-05280014 ErB2 HER2+ Paclitaxel Pfizer MGAH22 ErB2 HER2+ Macrogenics Study Drug(s) Target Biomarkers/ Subtype Combination Sponsor